In addition, this release is mediated as a result of changes in pH through the uptake of H+ by ion channels such as polycystic kidney disease proteins 1 like 3 and 2 like 1 (PKD1L3, PKD2L1), inward rectifying K+ channel (KIR2.1) and the epithelial Na+ channel (ENaC) [4142434445]
Recent Findings The ability of adipocytes to synthesize lipids from glucose is a marker of metabolic fitness, e.g., low de novo lipogenesis (DNL) in adipocytes correlates with insulin resistance in obesity
There's plenty of patients who come in with lower BMI who are like, I just want to get down to that high school weight, Dr
Sermorelin is a peptide therapy designed to stimulate the bodys natural production of growth hormone, and many
Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation
Acetyl-CoA carboxylase 1 regulates endothelial cell migration by shifting the phospholipid composition
